Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Nexstim Plc: Managers' Transactions, Weckroth
Company Announcement, Helsinki, 25 April 2024 at 1:05 PM (EEST) Nexstim Plc: Managers' Transactions, Weckroth Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Tero Weckroth Position: Member of the Board/Deputy member Issuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 59511/5/4____________________________________________…
Nasdaq GlobeNewswire
25/04/2024
Nexstim Plc: Managers' Transactions, Niemistö
Company Announcement, Helsinki, 25 April 2024 at 1 PM (EEST) Nexstim Plc: Managers' Transactions, Niemistö Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces managers' transactions as follows:Person subject to the notification requirement Name: Leena Niemistö Position: Member of the Board/Deputy member Issuer: Nexstim Oyj LEI: 743700S7ZI0LNMHZ6Y27 Notification type: INITIAL NOTIFICATION Reference number: 59505/5/4____________________________________________…
Nasdaq GlobeNewswire
25/04/2024
Orion Group Interim Report January–March 2024
ORION CORPORATIONINTERIM REPORT 1-3/2024 25 APRIL 2024 at 12:00 EESTOrion Group Interim Report January–March 2024Net sales totalled EUR 308.5 (January–March 2023: 277.9) million Operating profit was EUR 56.0 (55.5) millionBasic earnings per share were EUR 0.31 (0.31)Cash flow from operating activities per share was EUR 0.78 (0.03) The outlook for 2024 has been specified regarding operating profit: Operating profit is estimated to be EUR 280 million to EUR 310...
Nasdaq GlobeNewswire
25/04/2024
The Balance HealthCare Group expands luxury mental health and addiction services…
Abdullah Boulad, CEO and Founder said: "The healthcare system today is broken down by symptoms. We know that those symptoms are only a sign of a deeper, underlying issue. We've been taught to look at our pain and problems in isolation - this misses so much of the human health experience. When you come to The Balance, you receive care that's inter-connected. Your therapist works with your doctor, works with your nutritionist, who works with you. We bring it all together. Which is why we're…
PR Newswire
25/04/2024
Enzymatica Interim report Q1/2024: MDR certification opens up great commercial…
CEO Comment CEO Comment "Sales for the first quarter were lower than the same period last year, which in its entirety is due to the low partner sales. In the Swedish market, sales were up by 21% compared to the same quarter last year, and our market share continues to increase. During the quarter, ColdZyme was MDR certified as one of the first cold products inEurope, which opens up great commercial opportunities. We can make stronger and better health claims, that will fortify our...
PR Newswire
25/04/2024
4 university colleges in Denmark join forces to enhance on-site and remote…
"We have previously used what you might call a lite version of the Sectra PACS with the purpose of making clinical images a part of our training program. By transferring to the education portal, we look forward to greatly enhancing the learning experience for our radiographer students. For the faculty, this will facilitate the development of tailored learning materials, lessons, and assessments, while enabling the sharing of material and lessons among the four universities and their…
PR Newswire
25/04/2024
Less than half of veterinary professionals feel their profession is appreciated
World Veterinary Day 2024 celebrates the essential work of veterinarians, yet new data show only 49% of veterinary professionals believe their profession is appreciated. Veterinary associations and Boehringer Ingelheim unite to help address this issue—starting with showcasing often-unseen aspects of the veterinary profession.The World Veterinary Association's theme for World Veterinary Day this year (April 27, 2024) highlights that veterinarians are essential health workers...
Nasdaq GlobeNewswire
25/04/2024
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Outlook 2024 - unchanged Outlook 2024 - unchanged The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excludingChina, Gamifant, Vonjo and Zynlonta ®, and royalty on Sanofi's sales on Altuviiio™ and Beyfortus. Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at16:00 CEST. The presentation can be followed livehere or afterwards on...
PR Newswire
25/04/2024
Indivior Announces Q1 2024 Financial Results
Webcast link: https://edge.media-server.com/mmc/p/hktzzit4Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519 Webcast link:https://edge.media-server.com/mmc/p/hktzzit4Participants may access the presentation telephonically by registering with the following link:https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519 (Registrants will have an option to be...
PR Newswire
25/04/2024
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in…
Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory…
PR Newswire
25/04/2024
Crossject reports audited financial results for 2023
Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free auto-injectors technology platform ZENEO®,reports its audited financial results for the year ending December 31, 2023. These results are now available on the Company's website.Key financial information as of December 31, 2023Crossject's financial results for the year ending December...
Nasdaq GlobeNewswire
25/04/2024
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins…
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidanceParis, April 25, 2024Sales growth of 6.7% at CER and business EPS (1)of €1.78Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and...
Nasdaq GlobeNewswire
25/04/2024
ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and…
Submitted FDA De Novo application for ARC-EX ®System Successfully raised EUR 20M in equity capitalAnnounced positive top-line results from Up-LIFT pivotal studyForged partnership to provide rapid access to US Veterans Health AdministrationContinued to pioneer brain-computer interface therapies for SCI EINDHOVEN, The Netherlands, April25, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord...
Nasdaq GlobeNewswire
25/04/2024
Essity's Interim Report, Quarter 1, 2024
CEO'S COMMENTS CEO'S COMMENTS Innovation-driven growth "Volume growth was positive for the quarter, except for the impact of restructuring measures implemented in Professional Hygiene and contracts exited in Incontinence Products Health Care. In Consumer Goods, Feminine Care gained market shares and Incontinence Products Retail continued to grow strongly. Essity is in better shape than ever. The pace of innovation is high, which provides us with a good foundation for growth moving...
PR Newswire
25/04/2024
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides…
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release.Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71...
Nasdaq GlobeNewswire
25/04/2024
Towards a New Era: Fashion Source, Shenzhen Original Design Fashion Week and PV…
The inspiring exhibition zones were a must-see. Exploring the theme of "Knit Cosmos", the Fashion Source 25SS Knitting Trends featured nearly 200 selected knitted panels juxtaposed with the Color Trend pieces, knitted garments and installation art, visualizing the latest shifts in knitwear. Moving to the Fashion Source U-Library zone, visitors could see and touch more than 300 pieces of selected fabrics while enjoying online services. On the topic of "MOVING TOGETHER", the…
PR Newswire
25/04/2024
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
The NDA is supported by results from JUPITER-02, a randomized, double-blind, placebo-controlled, multinational multi-center Phase 3 clinical study (NCT03581786) that examined toripalimab in combination with gemcitabine-cisplatin as the first-line treatment of NPC, as well as results from POLARIS-02, a multi-center, open-label, pivotal Phase 2 clinical study (NCT02915432) that evaluated toripalimab as the second-line or later treatment for recurrent or metastatic NPC.Results from...
Nasdaq GlobeNewswire
25/04/2024
Stargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsight
Key Takeaways from the Stargardt Disease Market Report Key Takeaways from the Stargardt Disease Market Report Discover which therapies are expected to grab the major Stargardt disease market share @Stargardt Disease Market Report Stargardt Disease Overview Stargardt disease, also called Stargardt's macular dystrophy or juvenile macular degeneration, is the most common type of macular degeneration seen in young individuals. Those affected by this condition experience a...
PR Newswire
24/04/2024
Vistin Pharma ASA: Annual Report 2023
Please find attached the Annual Report for 2023 for Vistin Pharma ASA. There are no material changes in the financial statements compared to the preliminary full year results presented on 16 February 2024.The annual report for 2024 will also be made available onwww.vistin.com.***** For further information, please contact: Alexander Karlsen CFO +47 97 05 36 21 Alexander.karlsen@vistin.com Attachments 2023 Annual Report Vistin Pharma ASAVistinpharmaasa-2023-12-31-en...
Nasdaq GlobeNewswire
24/04/2024
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and neck cancer; initial efficacy and favorable safety profile supports potential of NBTXR3 in pancreatic cancer; determined RP2D for MD Anderson lung studyMultiple clinical readouts expected in 2024 including immunotherapy combination data...
Nasdaq GlobeNewswire
24/04/2024
Europe Camping Tents Market to Gear Up with $1.5 Billion Revenue by 2029 -…
The Europe Camping Tents Market Report Scope The Europe Camping Tents Market Report Scope Consumers acrossEuropeare progressively gravitating towards camping tent designs, prioritizing lightweight and portability. This inclination underscores a desire for seamless outdoor experiences, where the ease of transportation becomes a paramount consideration. The market responds by offering innovative designs that provide shelter and align with the contemporary demand for hassle-free and...
PR Newswire
24/04/2024
Calliditas Therapeutics' 2023 Annual Report Published
Åsa Hillsten, Head of IR & Sustainability, CalliditasTel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email:asa.hillsten@calliditas.com This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was sent for publication, through the agency of the contact persons set out above, onApril 24, 2024, at7:00 p.m...
PR Newswire
24/04/2024
Groupe Casino: BUT, Conforama, MDA Company, Casino Group and Intermarché end…
Press release Paris, 24 April 2024BUT, Conforama, MDA Company, Casino Group and Intermarché end their technical goods *purchasing partnership,Sirius AchatsAfter almost two years, BUT, Conforama, MDA Company, Casino Group and Intermarché have decided, in accordance with the terms of their agreements, to terminate their central purchasing hub Sirius Achats with effect from 15 June 2024. Each banner can now forge new partnerships in technical goods purchasing or deepen...
Nasdaq GlobeNewswire
24/04/2024
Estithmar Holding reinforces its expansion in the healthcare sector in Iraq by…
The agreement was signed by Dr. Sabah Noor Al-Musawi, Director General of Karbala Health and Eng. Mohammed bin Bader Al-Sadah, in his capacity as Group CEO of Estithmar Holding. The agreement was signed by Dr. SabahNoor Al-Musawi, Director General of Karbala Health and Eng.Mohammed bin Bader Al-Sadah, in his capacity as Group CEO of Estithmar Holding. On this occasion, Eng.Mohammed bin Bader Al-Sadah, Group CEO of Estithmar Holding, commented on Elegancia Healthcare's expansion in...
PR Newswire
24/04/2024
Altri Comunicati
